Veerle Hufkens

Statistics

Publications

Citations

253

H-Index

Active since

2017

Affiliations

Janssen (Belgium)(Current)

University of North Carolina at Chapel Hill

Assistance Publique – Hôpitaux de Paris

Université Paris Cité

Délégation Paris 7

Veerle Hufkens is an author at Janssen (Belgium) specializing in antiretroviral therapy, human immunodeficiency virus pharmacotherapy, and antiviral pharmacotherapy.

Publications per year

2017–2019

Publications

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Chloe Orkin, Jean‐Michel Molina, Eugènia Negredo et al. · The Lancet HIV · 2017 · 96 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients

Joseph J. Eron, Chloe Orkin, Joel E. Gallant et al. · AIDS · 2018 · 85 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Joseph J. Eron, Chloe Orkin, Douglas Cunningham et al. · Antiviral Research · 2019 · 36 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients

Chloe Orkin, Joseph J. Eron, Jürgen K. Rockstroh et al. · AIDS · 2019 · 36 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

1–4 of 4